Industry News
Biotechnology Industry News
Sanofi’s head of R&D, Houman…
Sanofi’s head of R&D, Houman Ashrafian, Ph.D., spoke to Fierce days before the company claimed a win for its anti-TNFa/OX40L nanobody in hidradenitis suppurativa.
Innate Pharma is set to lose 30%…
Innate Pharma is set to lose 30% of its employees, including its chief scientific officer, as the French biotech focuses on its “highest-value assets.”
With drugmakers freezing…
With drugmakers freezing investment in the U.K., pharma trade group ABPI has set out its vision for how Scotland can buck the trend and become a leader in R&D and cutting-edge medicines.
During his tenure at Genentech,…
During his tenure at Genentech, ophthalmologist Jason Ehrlich supported the development of Roche’s blockbuster eye disease med Vabysmo. Now, as the co-founder and CEO of newly launched Ollin Biosciences, Ehrlich seeks to topple the titan
Politicians scrambled to arrange…
Politicians scrambled to arrange the committee hearing after a string of Big Pharmas announced moves last week to close R&D sites or pause future funding decisions.
Genmab has dropped an…
Genmab has dropped an antibody-drug conjugate picked up as part of its $1.8 billion ProfoundBio buyout, citing an inadequate benefit-risk profile.
Apollo Therapeutics’ $15 million…
Apollo Therapeutics’ $15 million bet on Avalo’s anti-IL-18 monoclonal antibody appears to have paid off after the candidate aced a phase 2 trial in atopic dermatitis.
Three years on from a splashy…
Three years on from a splashy unveiling, Areteia Therapeutics has reported a phase 3 victory that could boost its bid to launch an oral rival to the biologics that dominate a multibillion-dollar asthma market.
The injectable amylin drug appears…
The injectable amylin drug appears to have slightly lower efficacy but a more tolerable profile than Novo's approved obesity blockbuster Wegovy.
CSL has moved quickly to spend…
CSL has moved quickly to spend some of the money freed up by recent cuts, securing an option to buy the phase 3-ready blood clotting specialist VarmX in return for $117 million upfront.
Flagship Pioneering’s Lila…
Flagship Pioneering’s Lila Sciences has landed a substantial $235 million series A as it looks to exceed the current limits of the drug discovery process through automation.
CatalYm has tapped four industry…
CatalYm has tapped four industry leaders to take up spots at the immunotherapy biotech, a move that has prompted three other executives to hit the exit.
Sanofi has become the latest Big…
Sanofi has become the latest Big Pharma to freeze R&D investment decisions in the U.K., while Roche isn't making any changes to its plans—for now.
A phase 3 trial of aTyr Pharma’s…
A phase 3 trial of aTyr Pharma’s efzofitimod in a lung disease has missed its primary endpoint. With a multibillion-dollar market in its sights, the biotech is planning to talk to the FDA about a
Novartis has stuck on a second…
Novartis has stuck on a second deal to its partnership with molecular glue degrader biotech Monte Rosa Therapeutics that includes a $120 million upfront payment.
AstraZeneca has paused a 200…
AstraZeneca has paused a 200 million pound sterling (about $271 million) investment in its Cambridge, England, research site, the latest Big Pharma to pull back from the U.K. this week, a company spokesperson has confirmed
Eli Lilly is reconsidering plans…
Eli Lilly is reconsidering plans for its U.K. biotech-focused Gateway Labs amid concerns about the industry’s outlook in the country and low government spend on drug development, according to reports from several outlets.
Maryland-based biotech Galimedix…
Maryland-based biotech Galimedix Therapeutics is ready to take a big swing on its oral Alzheimer’s disease candidate after the small molecule caused no serious adverse events and successfully crossed the blood-brain barrier in a phase
With its head of U.S. business…
With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona Pacheco. Pacheco is set to leave behind her role as Eli
FibroGen has agreed to pay $1.25…
FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission to address allegations that its former chief medical officer manipulated data for the anemia drug roxadustat.